Background {#s1}
==========

Brucella spp. is a Gram-negative, nonencapsulated, flagellated, facultatively intracellular coccobacilli, causing of brucellosis, which is a zoonosis transmitted from animals to humans by ingestion of contaminated foods such as milk products, direct contact with an infected animal, or inhalation of aerosols . Four species of Brucella out of eight are known to cause disease; they are B. abortus, B. canis, B. suis, and B. melitensis which infect livestock and could also infect a human \[[@R01]\]. Brucella melitensis causes Ovine Brucellosis, along with Brucella ovis. It can infect sheep, cattle, and sometimes humans and transmitted by the stable fly, unlike Brucella ovis, causing Malta fever or localized brucellosis in humans.

The global burden of human brucellosis has been estimated more than 5 lakh human infections per year worldwide \[[@R02]\]. Brucella species have been reported to acquire antibiotic resistance resulting very difficult to treat. This bacteria could reside inside the host\'s cells and is able to envade the immune response and inhibit programmed cell death which provides it an extended life span \[[@R03],[@R04]\]. The comparative efficacy of standard antibiotics on this intracellular pathogen and antibiotic resistance hamper successful treatment of the infection. Therefore combinations of the antibiotics: doxycycline, rifampin and streptomycin are applied in order to avoid relapses and to prevent prolonged use of these drugs include \[[@R05]\]. The therapeutic failures have been reported due to antibiotic resistance, which is associated with increasing prevalence of drug-resistance genes for the brucellosis first-line treatment options \[[@R06],[@R07]\]. This situation demands to discover novel drug candidates to combat Brucella's infection. In order to that researchers are applying molecular target based drug development. Among various molecular targets, methionyltRNA synthetase (MetRS) (generating increased interest from a drug development standpoint) is an excellent target for discovery of new drugs against Brucella. This protein is attracting very interest for drug development because it involves in cell protein translation processes \[[@R08]\]. MetRS is a novel target because it links tRNA with methionine for elongation in protein synthesis as well as with the initiator tRNA with methionine for protein synthesis \[[@R09]\]. In this study, we describe virtual screening of inhibitors of MetRS of B. melitensis (MetRSBm) by using the antimycobacterial library from ChEMBL Bioassay, approved drug dataset, Natural Products Set IV and Methionine analogous dataset. The novel potential inhibitors described in this research could be better as compared to the known inhibitors of MetRSBm.

Methodology {#s2}
===========

Identification of Positive Control {#s2a}
----------------------------------

Positive control dataset consists of molecules identified for their inhibitory effect against Methionyl-tRNA-Synthetase enzyme from a survey of the literature. 2-({3-\[(3,5-dichlorobenzyl) amino\] propyl} amino)quinolin-4(1H)-one(1312), 1-{3-\[(3-chloro-5- ethoxybenzyl) amino\] propyl}- 3-phenylurea (1415), and 1-{3- \[(3,5-dichlorobenzyl)amino\] propyl} -3- thiophen-3-ylurea\] (1430) \[[@R10]\], are present in positive control library.

Datasets for High throughput virtual screening {#s2b}
----------------------------------------------

A library of 56,400 compounds was obtained from the ChEMBL antimycobacterial database used for finding novel inhibitors against MetRSBm \[https://www.ebi.ac.uk/chembl/\]. An approved drug dataset containing 1596 compounds was extracted from drug bank (http://www.drugbank.ca/), The Natural Products Set IV consists of 419 compounds that were selected from the DTP Open Repository collection of 140,000 compounds. Factors in selection were origin, purity, structural diversity and availability of compound. (https://wiki.nci.nih.gov/display/NCIDTPdata/Compound+Se ts), and 2396 Methionine analogous were extracted from NCBI PubChem (pubchem.ncbi.nlm.nih.gov). Molecule Preprocessing of ligand molecules involved the conversion of dimension from 2D to 3D and conversion of file format to .sdf using Corina 2.64v software \[[@R11]\].

Docking and Scoring {#s2c}
-------------------

Molecular docking was performed using GLIDE module of Schrödinger Maestro, Version 9.1 \[[@R12]\] using against the MetRsBm. Adding hydrogen and generating conformations through the LigPrep module first prepared the ligand libraries. This LigPrep module generated tautomer with the OPLS2005 force field. The total no. of 141476, 2110, 5276, and 5782 output structures were obtained from ChEMBL antimycobacterial dataset, approved drugs, Natural product IV, and Methionine analogus dataset respectively.

The crystal structure of MetRsBm (4DLP) was obtained from protein data bank (http://www.rcsb.org/pdb/explore.do? structureId=4DLP). The protein was prepared by removing of other chain, waters, and heteroatoms, by adding hydrogen, and energy minimized at 0.30 Å RMSD using Prot-Prep module. The glide module is built upon a grid-based algorithm that requires grid generation in the active site of the target protein. Then, A 10 × 10 × 10 Å grid was generated around on the active site of the target protein Tyr35, Asp72, Val250, Trp251, Asp253, Ala254, Leu255, Asn257, and Tyr258. The ligands were flexibly docked on the protein structure. The non-planar conformations were penalized. The ligands were having more than 200 atoms or more than 35 rotatable bonds were not docked. Also, the Van Der Waal\'s radius scaling factor was set to 0.8, and the partial charge cutoff was set to 0.15. In GLIDE docking, the top 10 compounds were selected based on extra precision G-score. The binding affinity of docked complexes was re-scored using X-Score v1.2.1 \[[@R13]\]. Protein-ligand interaction was analyzed by using Pymol version 1.1r. www.pymol.org and LigPlot+ v1.4.5.

Results and Discussion {#s3}
======================

Docking analysis of known inhibitors of MetRSBm {#s3a}
-----------------------------------------------

The molecular docking of known inhibitors of MetRSBm was done using glide module. All three known inhibitors showed Gscore from -3.88 to -3.17 kcal/mol and predicted binding energy from -8.66 to -8.30 kcal/mol (calculated using the X-Score) ([Table 1](#T1){ref-type="table"}). The Ligplot+ analysis showed that His44, Lys77, Gln173, and Trp251 amino acids interact by h-bond interaction, with docked ligands. These results suggest that the novel MetRSBm inhibitors could be designed considering parameters of docking results leading to new potent drugs against Brucella.

Screening of ChEMBL antimycobacterial library against MetRSBm {#s3b}
-------------------------------------------------------------

ChEMBL antimycobacterial dataset (56400) was subjected to molecular docking. The top 10 compounds (after docking), based on their G-score are shown in [Table 2](#T2){ref-type="table"}. The glide score of these compounds varies from -10.27 to -8.42 (in kcal/mol). The G-score indicated that these compounds have a good binding affinity for MetRSBm enzyme. [Figure 1](#F1){ref-type="fig"} showed the docked complex of ligand Amikacin in the active site of the receptor with best Gscore (-12.27 kcal/mol). To further validate in silico, predicted binding affinity of the best pose obtained from docking studies for each compound was calculated using X-score program was found to be in between -9.27 and -7.25 kcal/mol shown in [Table 2](#T2){ref-type="table"}.

We analyzed the types of interactions of each top ranked ChEMBL antimycobacterial compound against MetRSBm; 2D plots were generated using Ligplot+ software and ligand-protein complex. The number of hydrogen bonded interactions, lipophilic interactions and the number of non-bonded interactions was counted and tabulated in [Table 2](#T2){ref-type="table"}. It is observed that overall all compounds from C1 to C10 have formed at least 1 (C2, C5, C6, C7, C9 and C10), mostly 5 (C1, and C4, and C8), and at most 7 (C3) hydrogen bonds. The total number of lipophilic interactions for each compound varies in between 15 (for C5) and 5 (for C1). Also, the total number of non-bonded interactions for each compound varies from 74 (for C5) to 29 (for C2). These observations suggest that the compounds C1, C3, C4, and C6 have better specificity as they have more hydrogen bonds and compounds C1, C3, C4, C5, C8 and C9 have good binding affinity due to a high number of hydrophobic contacts. The Compound C1 showed interaction with Glide score -12.27 kcal/mol. The docking poses analysis of C1shows five hydrogen bonds (His44, Lys77, Asp15, Gln173, and Asp285) interaction with amino acid residues of the protein. The Compound C3 showed highest seven hydrogen bond interaction with the active site residues Ile33, Tyr35, Asn37, Lys77, Gln173, Tyr258, and Asp285, with Gscore of -9.56 kcal/mol, 56 nonbonded interactions, and six hydrophobic interactions (Ala32, Ala34, Trp251, Asn257, Leu255, and His290). Tyr35, His44, Tyr258, Asp285, and Ile286 are found to be the most conserved residues, which is present in at least 8 out of 10 compounds. Hence, based on the Docking analysis against MetRSBm inhibitors, we conclude that these compounds have a better affinity with MetRSBm enzyme, thus are novel potential candidate to develop drugs against Brucella.

Further, we also analyzed the interactions of approved drugs Library's top ranked inhibitors against MetRSBm ([Table 3](#T3){ref-type="table"}). The highest X score of -8.40kcal/mol was obtained with the Hexoprenaline drug having four hydrogen bonds (Ile33, Tyr155, Lys225, and Tyr249) interaction with amino acid residues of the protein. The total number of lipophilic interaction for each compound varies in between 11 (C4 and C6) and 4 (for C10). The Compound C7 showed highest seven hydrogen bond interactions with the active site residues (Ile33, Tyr35, His41, His44, Asp72, and Arg151) have good specificity and C4 and C6 have a good binding affinity. Ala34 amino acid is present in 10 out of 10 compounds, and Gln173, Trp251, and Ile286 8 out of 10 compounds are found to be the most conserved residues. Hence, based on the comparison between known MetRSBm inhibitors (as control) and top ten potent drugs, we conclude that these compounds could bind to MetRSBm with better affinity, thus are the potential candidate to develop drugs against Brucella.

Additionally, we also analyzed the interactions of Natural Product IV Library's top ranked inhibitors against MetRSBm ([Table 4](#T4){ref-type="table"}). [Figure 2](#F2){ref-type="fig"} shows the docked complex of ligand Prumycin in the active site of the receptor with best G-score (- 10.55 kcal/mol). The highest X score of -9.43 kcal/mol was obtained with the Chartreusin compound (C5) having two Hbond (Lys77, and Gln173) and G-Score -10.55 kcal/mol four Hbond (Ile33, Tyr35, Asp72, Gly283) interaction with amino acid residues of the protein. The total number of lipophilic interaction for each compound varies in between 14 (C6) and 4 (for C7). The Compound C1, C3, and C7 showed highest four hydrogen bond interactions with the active site residues have good specificity, and C6 have a good binding affinity. Ala32 is present in 10 out of 10 compounds, Trp251 and Ile286 are present in 9 out of 10 compounds, and Tyr35, Gln47 and Asp285 are found to be the most conserved residues, which is present in 8 out of 10 compounds. Hence, based on the comparison between known MetRSBm inhibitors (as control) and top ten potent drugs, we conclude that these compounds could bind to MetRSBm with better affinity, thus are the potential candidate to develop drugs against Brucella.

Interestingly, we also analyzed the interactions of methionine analogous Library's top ranked inhibitors against MetRSBm ([Table 5](#T5){ref-type="table"}). [Figure 3](#F3){ref-type="fig"} shows the docked complex of ligand C1 compound in the active site of the receptor with the highest Gscore (-11.20) and X-score and -9.23 kcal/mol having two hydrogen bond (Ile33, and Arg151) interaction with amino acid residues of the protein. The total number of lipophilic interaction for each compound varies in between 14 (C7) and 7 (for C9). The Compound C2 and C9 showed highest seven hydrogen bond interaction with the active site residues have good specificity and C2, C4, C5, C6, C8, and C10 have a good binding affinity. Hence, based on the comparison between known MetRSBm inhibitors (as control) and top ten novel compounds, we conclude that these compounds could bind to MetRSBm with better affinity, thus are the potential candidate to develop drugs against Brucella.

Conclusion {#s4}
==========

We extrapolate that the analogous of methionine for find novel drug likeness has been identified \[4-(L-histidyl)-2-phenylbenzoyl\] methionine hydrochloride, might show the inhibitor of Brucella melitensis effect by interacting with MetRS enzyme. In this study, we extrapolate that the analogous of methionine for find novel drug likeness has been identified \[4-(L-histidyl)-2-phenylbenzoyl\] methionine hydrochloride, might show the inhibitor of Brucella melitensis effect by interacting with MetRS enzyme. We suggests that Prumycin as a natural product is the novel drugs for brucellosis.
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###### Molecular Docking results of the known inhibitors against MetRsBM

  S. No.   Compound ID         IUPAC Name                                                                 G Score (kcal/mol)   X-Score (kcal/mol)   H Bond                  Hydrophobic Interactions                                              No. of NB Interactions
  -------- ------------------- -------------------------------------------------------------------------- -------------------- -------------------- ----------------------- --------------------------------------------------------------------- ------------------------
  1        1415, CID60195001   1-\[3-\[(3-chloro-5-methoxyphenyl)methylamino\]propyl\]-3-phenylurea       -3.88                -8.66                Gln173, Trp251          Ala32, Tyr35, Lys77, Ala154, Tyr156, Tyr249, Asp285, Ile286, Phe289   44
  2        1433 CID60195274    1-\[3-\[(3,5-dichlorophenyl)methylamino\]propyl\]-3-thiophen-3-ylurea      -3.85                -8.03                Lys77, Trp251           Ala32, Ile33, Tyr35, Asp152, Ala154, Tyr156, Gln173, Tyr249, Phe289   33
  3        1312, CID18353708   2-\[3-\[(3,5-dichlorophenyl)methylamino\]propylamino\]-1H-quinolin-4-one   -3.17                -8.3                 His44, Lys77, Asp285,   Ala32, Tyr35, Glu47, Gln173, Trp251, Ile286, Phe289                   30

###### Top scoring 10 potential inhibitors from CHEMBL anti-myco-bacterial library against MetRsBM.

  S. No.   Compound ID     IUPAC Name                                                                                                                                                                                                                                        G Score (in kcal/mol)   X-Score (kcal/mol)   H Bond                                               Hydrophobic Interactions                                                                                    No. of NB Interactions
  -------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- -------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------
  C1       CHEMBL177       (2S)-4-Amino-N-\[(2S,3S,4R,5S)-5-amino-2-\[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl\]oxy-4-\[(2R,3R,4S,5R,6R)-6-(aminomethyl)-3,4,5-trihydroxy-oxan-2-yl\]oxy-3-hydroxy-cyclohexyl\]-2-hydroxybutanamide                 -10.27                  -7.91                His44, Lys77, Asp15, Gln173, Asp285                  Arg151, Tyr156, Ile286, Trp251, Phe289                                                                      52
  C2       CHEMBL235241    N\'-(7-chloroquinolin-4-yl)propane-1,3-diamine                                                                                                                                                                                                    -9.6                    -7.25                Ile33, Asp72                                         Ala34, Tyr35, Glu47, Trp251, Ala254, Asp285, Ile286                                                         29
  C3       CHEMBL471678    3-(2,3-dihydroxy-3-methylbutyl)-6-hydroxy-2-\[(1E,5E)-3,4,10-trihydroxyundeca-1,5-dienyl\]benzaldehyde                                                                                                                                            -9.56                   -8.61                Ile33, Tyr35, Asn37, Lys77, Gln173, Tyr258, Asp285   Ala32, Ala34, Trp251, Leu255, Asn257, His290                                                                56
  C4       CHEMBL1644895   (2S)-N-\[\[(2R,3S,4R,5R)-5-(2,4-dioxo-1,3-diazinan-1-yl)-3,4-dihydroxyoxolan-2-yl\]methyl\]-3-(1H-imidazol-5-yl)-2-\[\[2-\[(2R,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl\]acetyl\]amino\]propanamide                               -9.52                   -8.49                Tyr35, His41, His44, Glu47, Lys77                    Asp15, Ala32, Ala34, Asn37, Gly38, Gln173, Trp251, Ile286, Phe289                                           65
  C5       CHEMBL2017735   3-\[4-\[(5-cyclopropyl-1H-pyrazol-3-yl)amino\]-6-\[2-(dimethylamino)ethylamino\]pyrimidin-2-yl\]benzonitrile                                                                                                                                      -9.29                   -9.27                Asp72                                                Ile33, Tyr35, Gly43, Glu47, Lys77, Gln173, Trp251, Ala254, Leu255, Tyr258, Asp285, Ile286, His290, Phe314   74
  C6       CHEMBL450837    N\'-(7-chloroquinolin-4-yl)-N-propylethane-1,2-diamine                                                                                                                                                                                            -8.6                    -7.57                Ile33                                                Ala32, Ala34, Tyr35, His44, Glu47, Asp72, Trp251, Ala254, His290, Phe314                                    33
  C7       CHEMBL240758    1-(4-bromophenyl)-3-imidazol-1-yl-2-(imidazol-1-ylmethyl)propan-1-one                                                                                                                                                                             -8.6                    -7.68                Tyr35                                                Ala32, Ile33, Ala34, His44, Glu47, Asp72, Trp251, Gly283, Asp285, Ile286, His312, Phe314                    41
  C8       CHEMBL1801945   \[(2R,3R,4S,5R,6R)-6-\[\[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo\[4,5-c\]pyridin-2-yl\]amino\]-5-\[\[(3S)-3-amino-6-\[\[(3S)-3,6-diaminohexanoyl\]amino\]hexanoyl\]amino\]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl\] carbamate   -8.52                   -7.44                Tyr35, His44, Glu47, Gln173, Asp285                  Asn37, His41, Asp152, Gly283, Ile286, His312, Phe314                                                        53
  C9       CHEMBL1200847   (4E)-4-\[2-\[4-(diaminomethylidene)cyclohexa-2,5-dien-1-ylidene\]ethylidene\]-3-oxocyclohexa-1,5-diene-1-carboximidamide                                                                                                                          -8.45                   -8.94                Asp152                                               Ala32, Ile33, Ala34, Tyr35, Glu47, Lys77, Gln173, Tyr251, Asp285, Ile286, Phe289,                           50
  C10      CHEMBL391443    1-(5-chlorothiophen-2-yl)-3-imidazol-1-yl-2-(imidazol-1-ylmethyl)propan-1-one                                                                                                                                                                     -8.42                   -7.45                Tyr35,                                               Ala32, Ile33, Ala34, His44, Glu47, Asp72, Trp251, ly283, Asp285, Ile286, His312, Phe314                     39

###### Top scoring 10 potential inhibitors from Approved drugs library against MetRs-BM.

  S. No.   Generic Name             G Score (in kcal/mol)   X-Score (kcal/mol)   H Bond                                      Hydrophobic Interactions                                                               No. of NB Interactions
  -------- ------------------------ ----------------------- -------------------- ------------------------------------------- -------------------------------------------------------------------------------------- ------------------------
  C1       Amikacin                 -9.08                   -7.86                His44, Lys77, Asp152, Gln173                Ala34, Tyr35, Arg151, Tyr156, Trp251, Asp285, Ile286, Phe289,                          52
  C2       adenosine triphosphate   -8.91                   -7.17                Tyr35, Asn37, His44, Lys77, Trp251          Ala34, Asp152, Gln173, Asp285, Ile286, Phe289,                                         35
  C3       Streptomycin             -7.53                   -7.23                Tyr35, His44, Asp285,                       Ala34, Gly43, Asp152, Gln173, Trp251, Ile286, Phe314                                   48
  C4       Aztreonam                -7.29                   -8.39                Asp72, Lys77                                Ala32, Ile33, Ala34, Tyr35, His44, Glu47, Trp251, Ala254, Asp285, Ile286, His312       60
  C5       Lymecycline              -7.06                   -8.15                Ile33, Lys77, Asp152                        Ala32, Ile33, Ala34, Tyr35, Asn37, His41, Arg151, Gln173, Thr175, Phe314,              38
  C6       Hexoprenaline            -6.83                   -8.4                 Ile33, Tyr155, Lys225, Tyr249               Ala32, Ala34, Tyr35, Asp152, Ala154, Gln173, Phe219, Trp251, Ile286, Phe289, Phe314,   51
  C7       Enviomycin               -6.72                   -7.44                Ile33, Tyr35, His41, His44, Asp72, Arg151   Ala34, Asn37, Lys77, Gln173, Trp251, Asp258, Phe314,                                   43
  C8       Fludarabine              -6.64                   -7.11                Lys77, Asp152, Gln173, Trp251               Ala32, Ile33, Tyr35, Ile286, Phe289,                                                   32
  C9       Adenylate                -6.63                   -7.14                Glu47, Gln173, Trp251, Asp285               Ala32, Ala34, Tyr35, Ile286, Phe289                                                    31
  C10      Paromomycin              -6.6                    -7.21                Tyr35, His44, Lys77, Asp285                 His41, Gln173, Ile286, Phe314                                                          29

###### Top scoring 10 potential inhibitors from natural product IV dataset against MetRs-BM.

  S. No.   Compound ID   Generic Name                      G Score (in kcal/mol)   X-Score (kcal/mol)   H Bond                                Hydrophobic Interactions                                                                                   No. of NB Interactions
  -------- ------------- --------------------------------- ----------------------- -------------------- ------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------
  C1       NSC 278619    Prumycin                          -10.55                  -6.74                Ile33, Tyr35, Asp72, Gly283           Ala34, Ala32, Glu47, Trp251, Ile286                                                                        36
  C2       NSC 100858    d-Inositol Kasugamycin            -9.38                   -7.62                Gln173, Trp251                        Ile33, Tyr35, Gly43, His44, Glu47, Lys77, Asp285, Ile286, Phe289, Phe314                                   36
  C3       NSC 256942    Epirubicin                        -8.66                   -8.71                His41, Glu47, Lys77, Gly283           Ala32, Ala34, His44, Asp152, Gln173, Trp251, Asp285, Ile286, Phe289, Phe314                                61
  C4       NSC 82151     Daunorubicin                      -7.86                   -9.24                Glu47                                 Ala32, Tyr35, Asn37, His41, His44, Lys77, Asp152, Gln173, Trp251, Gly283, Aps285, Ile286, Phe289, Phe314   55
  C5       NSC 5159      Chartreusin                       -7.27                   -9.43                Lys77, Gln173                         Ala32, Ile33, Ala34, Tyr35, Gly43, His44, Glu47, Arg151, Trp251, Aps285, Ile286,                           57
  C6       NSC 32944     (-)-Cephaeline, dihydrochloride   -7.22                   -9                   Lys77                                 Ala32, Ile33, Ala34, His41, Gly43, His44, Glu47, Asp152, Gln173, Trp251, Aps285, Ile286, Phe314            53
  C7       NSC 2080      Melezitose                        -6.95                   -6.87                Tyr35, Asn37, Lys77, Gln173, Asp285   Ala32, Ala34, His44, Ile286                                                                                34
  C8       NSC 105827    Thiosangivamycin                  -6.28                   -7.04                His44, Gln173, Trp251                 Ala32, Tyr35, Lys77, Asp285, Ile286, Phe289                                                                24
  C9       NSC 407308    Sakuranin                         -6.14                   -8.57                Glu47, Asp152                         Ala32, Ile33, Ala34, Tyr35, Gly43, His44, Lys77, Gln173, Trp251, Ile286, Phe289, His312, Phe314            54
  C10      NSC 12865                                       -6                      -7.46                Asp285                                32, Ile33, Ala34, Tyr35, Trp251, Phe314                                                                    38

###### Top scoring 10 potential inhibitors from Methionine analogus against MetRs-BM.

  S. No.   Compound ID    G Score ( in kcal/mol)   X-Score (kcal/mol)   H Bond                                               Hydrophobic Interactions                                                                                   No. of NB Interactions
  -------- -------------- ------------------------ -------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------
  C1       CID 69893052   -11.2                    -9.23                Ile33, Arg151                                        Ala32, Tyr35, Asp72, Trp251, Ala254, Asn257, Tyr258, Ile286, Phe289, His290, Gln173                        68
  C2       CID 18244364   -11.03                   -8.95                Ile33, Tyr35, Glu47, Asp72, Lys77, Arg151, Asp285    Ala32, Ala34, Asp152, Gln173, Gly174, Thr175, Trp251, Ala254, Phe289                                       82
  C3       CID 19881009   -10.7                    -8.27                Ile33, Tyr35, Glu47, Asp72, Lys77, Arg151, Gln173,   Ala32, Ala34, His44, Trp251, Gly283, Asp285, Ile286, His290, His312                                        61
  C4       CID 71464640   -10.04                   -7.5                 Lys77, Asp285                                        Ala32, Ile33, Ala34, Tyr35, Gly38, Lys39, His41, Glu47, Asp72, Asp152, Gln173, Trp251, Ile286              65
  C5       CID 2279       -10.04                   -8.66                Lys77, Arg151                                        Ala32, Ile33, asp72, Asp152, Gln173, Trp251, Ala254, Tyr258, Asp285, Ile286, Phe289, His290                76
  C6       CID 18408186   -9.94                    -8.14                Ile33                                                Ala32, Ala34, Tyr35, His44, Glu47, Asp72, Trp251, Ala254, Leu255, Tyr258, Ile286, His290,                  53
  C7       CID 7005065    -8.91                    -7.96                Ile33                                                Ala32, Ala34, Tyr35, His44, Glu47, Asp72, Trp251, Ala254, Leu255, Asn257, Tyr258, Ile286, His290, Phe314   47
  C8       CID 54604718   -8.74                    -7.93                Ile33, Tyr35, His290,                                Ala34, His44, Asp72, Lys77, Gln173, Trp251, Ala254, Asn257, Tyr258, Asp285, Ile286, Phe289,                55
  C9       CID 71402635   -8.63                    -7.95                Ile33, Tyr35, Glu47, Asp72, Lys77, Gln173, Asp285    Ala32, Asn37, His44, Trp251, Ala254, Ile286, Phe314                                                        58
  C10      CID 44384676   -8.51                    -7.66                Trp251, Asp285,                                      Ala32, Ile33, Ala34, Tyr35, Asp72, Lys77, Gln173, Ala254, Leu255, Tyr258, Phe289, His290,                  66

![Inhibitor ligand CHEMBL177 or Amikacin (ChEMBL antimycobacterial dataset) bound to the active sites of the MetRSBm. (A) Details of MetRSBm-ligand interaction. Key residues within 5.0 sphere of top-ranked in the binding pocket are shown. (B) Purple colour molecular surface shows the active site cleft in which compound ligand binds.](97320630013008F1){#F1}

![Inhibitor ligand Prumycin NSC278619 (Natural Product IV) bound to the active sites of the MetRSBm. (A) Details of MetRSBm-ligand interaction. Key residues within 5.0 sphere of top-ranked in the binding pocket are shown. (B) Magenta colour molecular surface shows the active site cleft in which compound ligand binds.](97320630013008F2){#F2}

![Inhibitor ligand CID69893052 (Methionine analogous) bound to the active sites of the MetRSBm. (A) Details of MetRSBmligand interaction. Key residues within 5.0 sphere of top-ranked in the binding pocket are shown; (B) ruby colour molecular surface shows the active site cleft in which compound ligand binds.](97320630013008F3){#F3}
